What is the role of molecular testing in the workup of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Molecular testing forms an important part of the full pathologic evaluation of patients with metastatic non–small cell lung cancer (NSCLC), because very effective, less toxic, targeted treatments have become available for NSCLC with specific molecular abnormalities. Testing should include the following:

  • Epidermal growth factor receptor ( EGFR) mutation
  • Anaplastic lymphoma kinase ( ALK) rearrangement
  • BRAF V600E  mutation
  • RET rearrangement
  • ROS-1 rearrangement
  • NTRK 1/2/3 gene fusion
  • MET exon 14 skipping
  • KRAS G12C mutation
  • Programmed death ligand 1 (PD-L1) expression

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!